[Hepatitis B recurrence after liver transplantation: efficacy and safety of intramuscular anti-hepatitis B immunoglobulins].
Ten to 25% of all patients undergoing liver transplantation (LT) have hepatitis B. LT outcome depends on the prevention of hepatitis B recurrence. In absence of prophylaxis the spontaneous risk for hepatitis B virus (HBV) reinfection is up to 75% but the major advances which have been made in prophylaxis in the last 15 years permit today the control of post-LT hepatitis B in more than 90% of patients. Anti-hepatitis B virus specific immunoglobulins (HBIG) play a major role in prophylaxis, in mono-therapy in non-replicating patients and combined with antivirals (lamivudine and/or adefovir-dipivoxil) in replicating subjects. In absence of standardized schedules of HBIG administration, the prevalent approach is the use of high doses (40 000-80 000 IU) of intravenous HBIG in the immediate peri-operative period (induction phase) and the administration of a monthly dose, fixed or on demand, of intravenous (6 000-10 000 IU) or intramuscular (2 000-4 000 IU) HBIG in the long-term (maintenance). In stable patients the combined-prophylaxis with antivirals permits a HBIG saving, in particular in on demand protocols; in this setting intramuscular HBIG are effective and safe in the maintenance phase.